PUBLISHER: Acute Market Reports | PRODUCT CODE: 1192937
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1192937
Vasculitis Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
Industry Outlook
The vasculitis treatment market expected to reach US$ 744.12 Mn by 2030 from US$ 407.8 Mn in 2021 and projected to exhibit a steady compound annual growth rate (CAGR) of 5.7% during the forecast period from 2022 to 2030. According to Vasculitis Foundation 2019 report, the global prevalence of vasculitis is 1-9 per 100,000 people. Vasculitis shows high degree of incidence in the Caucasian population and is widely prevalent in the Scandinavian countries. Earlier cyclophosphamide was considered as the first line of treatment for all types of vasculitis. In 2010, United States Food and Drug Administration (USFDA) had approved rituximab for the treatment of vasculitis along with prednisolone. Pharmaceutical and biotechnology industries are constantly striving to achieve a targeted drug therapy approach for the treatment of vasculitis majorly focusing on monoclonal antibodies such as tocilizumab, mepolizumab and infliximab. CCX168 developed by ChemoCentryx, currently under phase II clinical trials is an immunosuppressant is projected to enter the market by 2021 and anticipated to register impressive growth during the forecast period for the treatment of ANCA associated vasculitis. In 2020, North America held the largest market share in the vasculitis treatment market on account of the developed healthcare infrastructure, increasing public health awareness resulting in early vasculitis diagnosis. North America is domicile to key players engaged in the treatment of vasculitis disease, contributes towards dominance of North America in this market. Asia Pacific will register significant growth during the forecast period owing to huge geriatric population suffering with large vessel vasculitis, and supportive regulatory environment for the treatment of vasculitis disease.
Better Clinical Outcomes in Vasculitis Treatment Will Contribute To the Biologics Segment Growth
Currently biologics are leading the market by drug class segment and will continue to showcase excellent growth during the forecast period. In 2010, USFDA gave approval to rituximab for the treatment of vasculitis disease in combination with prednisolone. The dosage regimen currently postulated for rituximab throughout the globe is 4+2 protocol. In 2020, Biologics comprised of 38.98% share in the drug class segment on account of better drug safety & efficacy and rising prevalence of antineutrophil cytoplasmic autoantibodies (ANCA) associated renal vasculitis in elderly population. The only limitation of using rituximab therapy is its high cost, which hinders treatment in poor nations. Cyclophosphamide are used in patients showing resistance to rituximab therapy and its relatively low treatment cost contributes to its market growth in developing nations.
Accurate Diagnosis of Small Vessel Vasculitis to Record Highest Double Digit CAGR during the Forecast Period
The challenge that usually occur during the diagnosis of vasculitis is its overlapping symptoms with other inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, etc. The ambiguity occurs due to non-specificity of serological markers and irrational tissue biopsy. The chief inflammatory mediator that occurs in the vasculitis disease onset is leucocytes. The factors responsible for the accurate diagnosis of vasculitis is the technological advancement in the diagnostic kits and availability of skilled workforce to perform the diagnosis. In 2020, large vessel vasculitis occupied 45% share in the overall vasculitis disease epidemiology. The key attributes favoring the dominance of large vessel vasculitis are the rising prevalence of immunocompromised patients and medicines related adverse events encountered in the Caucasian populations. Small vessel vasculitis will be showcasing impressive growth during the forecast period owing to the increasing number of blood vessel aneurysm cases encountered in the Mongolian population and rampant growth in the reported cases of small vessel vasculitis initiated due to pesticide and chemical exposure.
Increasing public health awareness in Asia Pacific to set the stage for swift growth during the forecast period
In 2021, North America occupied 35.96% of the global market share for vasculitis treatment. The key factors responsible for the North America market growth are rising prevalence of large vessel vasculitis, presence of key players such as Bristol Myers Squibb Company, Celgene Corporation etc., and existence of advanced healthcare facilities. Asia Pacific will be the fastest growing market on account of large geriatric population suffering with small vessel vasculitis, enhanced funding by the pharmaceutical companies in the R&D segment and rising public health awareness resulting in early diagnosis and treatment.
Market assessment is performed in order to understand the prevailing market trends in the vasculitis treatment market. Market estimation is done by providing the compounded annual growth rate (CAGR) and data forecast for 2022-2030. Product portfolio is helpful in giving information of the FDA approved drugs currently prescribed for the treatment of vasculitis disease. Strategic collaboration, merger and acquisition among the key players for developing impressive product pipeline are mentioned in the business strategy section. The key players currently engaged in the Vasculitis Treatment market are F.Hoffman La-Roche Ltd., AstraZeneca, Baxter International, Bristol Myers Squibb Company, Celgene Corporation, ChemoCentryx, Daiichi Sankyo, Eli Lilly & Company, GlaxosmithKline Plc, Merck & Co., and Novartis AG.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Vasculitis Treatment market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Vasculitis Treatment market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Drug
Biologics
Rituximab
Infliximab
Adalimumab
Corticosteroids
Prednisone
Methylprednisolone
Immunosuppressant
Pipeline Analysis
Tabular Representation of Phase I and Phase II Drugs
Disease Condition
Large Vessel Vasculitis
Medium Vessel Vasculitis
Small Vessel Vasculitis
Region Segment (2020-2030; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Global Impact of COVID-19 Segment (2020-2021; US$ Million )
Pre COVID-19 situation
Post COVID-19 situation
Key questions answered in this report
What are the key micro and macro environmental factors that are impacting the growth of Vasculitis Treatment market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2030.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Vasculitis Treatment market?
Which is the largest regional market for Vasculitis Treatment market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Vasculitis Treatment market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Vasculitis Treatment market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Vasculitis Treatment Market
- 2.2. Global Vasculitis Treatment Market, By Drug, 2021 (US$ Million)
- 2.3. Global Vasculitis Treatment Market, By Disease Condition, 2021 (US$ Million)
- 2.4. Global Vasculitis Treatment Market, By Geography, 2021 (US$ Million)
- 2.5. Attractive Investment Proposition by Geography, 2021
3. Vasculitis Treatment Market: Competitive Analysis
- 3.1. Market Positioning of Key Vasculitis Treatment Market Vendors
- 3.2. Strategies Adopted by Vasculitis Treatment Market Vendors
- 3.3. Key Industry Strategies
- 3.4. Tier Analysis 2021 Versus 2030
4. Vasculitis Treatment Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Vasculitis Treatment Market Value, 2020 - 2030, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
5. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2021 Versus 2030
- 5.3. Market Segmentation
- 5.3.1. Biologics
- 5.3.1.1. Rituximab
- 5.3.1.2. Infliximab
- 5.3.1.3. Adalimumab
- 5.3.2. Corticosteroids
- 5.3.2.1. Prednisone
- 5.3.2.2. Methylprednisolone
- 5.3.3. Immunosuppressant
- 5.3.4. Pipeline Analysis
- 5.3.5. Tabular Representation of Phase I and Phase II Drugs
- 5.3.1. Biologics
6. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2021 Versus 2030
- 6.3. Market Segmentation
- 6.3.1. Large Vessel Vasculitis
- 6.3.2. Medium Vessel Vasculitis
- 6.3.3. Small Vessel Vasculitis
7. North America Vasculitis Treatment Market, 2020-2030, USD (Million)
- 7.1. Market Overview
- 7.2. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 7.3. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 7.4.Vasculitis Treatment Market: By Region, 2020-2030, USD (Million)
- 7.4.1.North America
- 7.4.1.1. U.S.
- 7.4.1.1.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 7.4.1.1.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 7.4.1.2. Canada
- 7.4.1.2.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 7.4.1.2.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 7.4.1.3. Rest of North America
- 7.4.1.3.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 7.4.1.3.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 7.4.1.1. U.S.
- 7.4.1.North America
8. UK and European Union Vasculitis Treatment Market, 2020-2030, USD (Million)
- 8.1. Market Overview
- 8.2. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 8.3. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 8.4.Vasculitis Treatment Market: By Region, 2020-2030, USD (Million)
- 8.4.1.UK and European Union
- 8.4.1.1. UK
- 8.4.1.1.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 8.4.1.1.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 8.4.1.2. Germany
- 8.4.1.2.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 8.4.1.2.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 8.4.1.3. Spain
- 8.4.1.3.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 8.4.1.3.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 8.4.1.4. Italy
- 8.4.1.4.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 8.4.1.4.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 8.4.1.5. France
- 8.4.1.5.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 8.4.1.5.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 8.4.1.6. Rest of Europe
- 8.4.1.6.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 8.4.1.6.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 8.4.1.1. UK
- 8.4.1.UK and European Union
9. Asia Pacific Vasculitis Treatment Market, 2020-2030, USD (Million)
- 9.1. Market Overview
- 9.2. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 9.3. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 9.4.Vasculitis Treatment Market: By Region, 2020-2030, USD (Million)
- 9.4.1.Asia Pacific
- 9.4.1.1. China
- 9.4.1.1.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 9.4.1.1.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 9.4.1.2. Japan
- 9.4.1.2.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 9.4.1.2.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 9.4.1.3. India
- 9.4.1.3.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 9.4.1.3.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 9.4.1.4. Australia
- 9.4.1.4.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 9.4.1.4.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 9.4.1.5. South Korea
- 9.4.1.5.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 9.4.1.5.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 9.4.1.6. Rest of Asia Pacific
- 9.4.1.6.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 9.4.1.6.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 9.4.1.1. China
- 9.4.1.Asia Pacific
10. Latin America Vasculitis Treatment Market, 2020-2030, USD (Million)
- 10.1. Market Overview
- 10.2. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 10.3. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 10.4.Vasculitis Treatment Market: By Region, 2020-2030, USD (Million)
- 10.4.1.Latin America
- 10.4.1.1. Brazil
- 10.4.1.1.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 10.4.1.1.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 10.4.1.2. Mexico
- 10.4.1.2.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 10.4.1.2.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 10.4.1.3. Rest of Latin America
- 10.4.1.3.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 10.4.1.3.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 10.4.1.1. Brazil
- 10.4.1.Latin America
11. Middle East and Africa Vasculitis Treatment Market, 2020-2030, USD (Million)
- 11.1. Market Overview
- 11.2. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 11.3. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 11.4.Vasculitis Treatment Market: By Region, 2020-2030, USD (Million)
- 11.4.1.Middle East and Africa
- 11.4.1.1. GCC
- 11.4.1.1.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 11.4.1.1.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 11.4.1.2. Africa
- 11.4.1.2.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 11.4.1.2.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 11.4.1.3. Rest of Middle East and Africa
- 11.4.1.3.1. Vasculitis Treatment Market: By Drug, 2020-2030, USD (Million)
- 11.4.1.3.1. Vasculitis Treatment Market: By Disease Condition, 2020-2030, USD (Million)
- 11.4.1.1. GCC
- 11.4.1.Middle East and Africa
12. Company Profile
- 12.1. F.Hoffman La Roche Ltd.
- 12.1.1. Company Overview
- 12.1.2. Financial Performance
- 12.1.3. Product Portfolio
- 12.1.4. Strategic Initiatives
- 12.2. AstraZeneca
- 12.2.1. Company Overview
- 12.2.2. Financial Performance
- 12.2.3. Product Portfolio
- 12.2.4. Strategic Initiatives
- 12.3. Baxter International
- 12.3.1. Company Overview
- 12.3.2. Financial Performance
- 12.3.3. Product Portfolio
- 12.3.4. Strategic Initiatives
- 12.4. Bristol Myers Squibb Company
- 12.4.1. Company Overview
- 12.4.2. Financial Performance
- 12.4.3. Product Portfolio
- 12.4.4. Strategic Initiatives
- 12.5. Celgene Corporaion
- 12.5.1. Company Overview
- 12.5.2. Financial Performance
- 12.5.3. Product Portfolio
- 12.5.4. Strategic Initiatives
- 12.6. ChemoCentryx
- 12.6.1. Company Overview
- 12.6.2. Financial Performance
- 12.6.3. Product Portfolio
- 12.6.4. Strategic Initiatives
- 12.7. Daiichi Sankyo
- 12.7.1. Company Overview
- 12.7.2. Financial Performance
- 12.7.3. Product Portfolio
- 12.7.4. Strategic Initiatives
- 12.8. Eli Lilly & Company
- 12.8.1. Company Overview
- 12.8.2. Financial Performance
- 12.8.3. Product Portfolio
- 12.8.4. Strategic Initiatives
- 12.9. GlaxoSmithKline Plc
- 12.9.1. Company Overview
- 12.9.2. Financial Performance
- 12.9.3. Product Portfolio
- 12.9.4. Strategic Initiatives
- 12.10. Merck & Co.
- 12.10.1. Company Overview
- 12.10.2. Financial Performance
- 12.10.3. Product Portfolio
- 12.10.4. Strategic Initiatives
List of Tables
- TABLE 1 Global Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 2 Global Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 3 Global Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 4 Global Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 5 North America Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 6 North America Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 7 North America Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 8 North America Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 9 U.S. Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 10 U.S. Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 11 U.S. Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 12 U.S. Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 13 Canada Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 14 Canada Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 15 Canada Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 16 Canada Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 17 Rest of North America Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 18 Rest of North America Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 19 Rest of North America Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 20 Rest of North America Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 21 UK and European Union Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 22 UK and European Union Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 23 UK and European Union Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 24 UK and European Union Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 25 UK Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 26 UK Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 27 UK Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 28 UK Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 29 Germany Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 30 Germany Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 31 Germany Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 32 Germany Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 33 Spain Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 34 Spain Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 35 Spain Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 36 Spain Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 37 Italy Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 38 Italy Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 39 Italy Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 40 Italy Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 41 France Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 42 France Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 43 France Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 44 France Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 45 Rest of Europe Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 46 Rest of Europe Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 47 Rest of Europe Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 48 Rest of Europe Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 49 Asia Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 50 Asia Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 51 Asia Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 52 Asia Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 53 China Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 54 China Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 55 China Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 56 China Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 57 Japan Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 58 Japan Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 59 Japan Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 60 Japan Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 61 India Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 62 India Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 63 India Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 64 India Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 65 Australia Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 66 Australia Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 67 Australia Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 68 Australia Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 69 South Korea Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 70 South Korea Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 71 South Korea Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 72 South Korea Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 73 Latin America Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 74 Latin America Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 75 Latin America Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 76 Latin America Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 77 Brazil Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 78 Brazil Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 79 Brazil Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 80 Brazil Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 81 Mexico Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 82 Mexico Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 83 Mexico Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 84 Mexico Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 85 Rest of Latin America Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 86 Rest of Latin America Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 87 Rest of Latin America Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 88 Rest of Latin America Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 89 Middle East and Africa Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 90 Middle East and Africa Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 91 Middle East and Africa Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 92 Middle East and Africa Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 93 GCC Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 94 GCC Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 95 GCC Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 96 GCC Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 97 Africa Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 98 Africa Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 99 Africa Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 100 Africa Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
- TABLE 101 Rest of Middle East and Africa Vasculitis Treatment Market By Drug, 2020-2030, USD (Million)
- TABLE 102 Rest of Middle East and Africa Vasculitis Treatment Market By Biologics, 2020-2030, USD (Million)
- TABLE 103 Rest of Middle East and Africa Vasculitis Treatment Market By Corticosteroids, 2020-2030, USD (Million)
- TABLE 104 Rest of Middle East and Africa Vasculitis Treatment Market By Disease Condition, 2020-2030, USD (Million)
List of Figures
- FIG. 1 Global Vasculitis Treatment Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Vasculitis Treatment Market: Quality Assurance
- FIG. 5 Global Vasculitis Treatment Market, By Drug, 2021
- FIG. 6 Global Vasculitis Treatment Market, By Disease Condition, 2021
- FIG. 7 Global Vasculitis Treatment Market, By Geography, 2021
- FIG. 8 Market Geographical Opportunity Matrix - Global Vasculitis Treatment Market, 2021
- FIG. 9 Market Positioning of Key Vasculitis Treatment Market Players, 2021
- FIG. 10 Global Vasculitis Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
- FIG. 11 Global Vasculitis Treatment Market, By Drug, 2021 Vs 2030, %
- FIG. 12 Global Vasculitis Treatment Market, By Disease Condition, 2021 Vs 2030, %
- FIG. 13 U.S. Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 14 Canada Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 15 Rest of North America Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 16 UK Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 17 Germany Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 18 Spain Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 19 Italy Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 20 France Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 21 Rest of Europe Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 22 China Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 23 Japan Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 24 India Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 25 Australia Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 26 South Korea Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 27 Rest of Asia Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 28 Brazil Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 29 Mexico Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 30 Rest of Latin America Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 31 GCC Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 32 Africa Vasculitis Treatment Market (US$ Million), 2020 - 2030
- FIG. 33 Rest of Middle East and Africa Vasculitis Treatment Market (US$ Million), 2020 - 2030
